Kelonia Therapeutics delivers impressive in vivo CAR-T update

All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy thus far have responded to treatment, according to an update shared Sunday. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…

Source: Endpoints News